STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

SELINEXOR

Generic	Brand	HICL	GCN	Exception/Other
SELINEXOR	XPOVIO	45854		

GUIDELINES FOR USE

1. Does the patient have a diagnosis of relapsed or refractory multiple myeloma (RRMM) and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - The requested medication will be used in combination with dexamethasone
   - The patient has received at least four prior therapies for the treatment of RRMM
   - The patient's RRMM is refractory to **ALL** of the following:
     - o Two proteasome inhibitors (e.g., bortezomib, carfilzomib)
     - o Two immunomodulatory agents (e.g., lenalidomide, pomalidomide)
     - o One anti-CD38 monoclonal antibody (e.g., daratumumab)

   If yes, **approve for 12 months by GPID for all strengths as follows:**
   - **Xpovio 60mg weekly dose (GPID 46637): #12 tablets per 28 days.**
   - **Xpovio 80mg weekly dose (GPID 46636): #16 tablets per 28 days.**
   - **Xpovio 100mg weekly dose (GPID 46635): #20 tablets per 28 days.**
   - **Xpovio 160mg weekly dose (GPID 46634): #32 tablets per 28 days.**

   If no, do not approve.
   DENIAL TEXT: The guideline named **SELINEXOR (Xpovio)** requires a diagnosis of relapsed or refractory multiple myeloma (RRMM). In addition, the following criteria must be met:
   - The patient is 18 years of age or older
   - The requested medication will be used in combination with dexamethasone
   - The patient has received at least four prior therapies for the treatment of RRMM
   - The patient's RRMM is refractory to **ALL** of the following:
     - o Two proteasome inhibitors (e.g., bortezomib, carfilzomib)
     - o Two immunomodulatory agents (e.g., lenalidomide, pomalidomide)
     - o One anti-CD38 monoclonal antibody (e.g., daratumumab)

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Xpovio.

REFERENCES

- Xpovio [Prescribing Information]. Newton, MA: Karyopharm Therapeutics Inc.; July 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A
Commercial Effective: 08/01/19
Created: 07/19
Client Approval: 07/19
P&T Approval: 07/19